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Background: Cancer stem cells are hypoxia-resistant and present a preponderant glycolytic metabolism. These
characteristics are also found in basal-like breast carcinomas (BLBC), which show increased expression of cancer
stem cell markers.
Recently, we demonstrated that P-cadherin, a biomarker of BLBC and a poor prognostic factor in this disease, mediates
stem-like properties and resistance to radiation therapy. Thus, the aim of the present study was to evaluate if P-cadherin
expression was associated to breast cancer cell populations with an adapted phenotype to hypoxia.
Methods: Immunohistochemistry was performed to address the expression of P-cadherin, hypoxic, glycolytic and
acid-resistance biomarkers in primary human breast carcinomas. In vitro studies were performed using basal-like breast
cancer cell lines. qRT-PCR, FACS analysis, western blotting and confocal microscopy were used to assess the expression
of P-cadherin after HIF-1α stabilization, achieved by CoCl2 treatment. siRNA-mediated knockdown was used to silence
the expression of several targets and qRT-PCR was employed to evaluate the effects of P-cadherin on HIF-1α signaling.
P-cadherin high and low breast cancer cell populations were sorted by FACS and levels of GLUT1 and CAIX were
assessed by FACS and western blotting. Mammosphere forming efficiency was used to determine the stem cell activity
after specific siRNA-mediated knockdown, further confirmed by western blotting.
Results: We demonstrated that P-cadherin overexpression was significantly associated with the expression of HIF-1α,
GLUT1, CAIX, MCT1 and CD147 in human breast carcinomas. In vitro, we showed that HIF-1α stabilization was
accompanied by increased membrane expression of P-cadherin and that P-cadherin silencing led to a decrease of the
mRNA levels of GLUT1 and CAIX. We also found that the cell fractions harboring high levels of P-cadherin were the same
exhibiting more GLUT1 and CAIX expression. Finally, we showed that P-cadherin silencing significantly decreases the
mammosphere forming efficiency in the same range as the silencing of HIF-1α, CAIX or GLUT1, validating that all these
markers are being expressed by the same breast cancer stem cell population.
Conclusions: Our results establish a link between aberrant P-cadherin expression and hypoxic, glycolytic and
acid-resistant breast cancer cells, suggesting a possible role for this marker in cancer cell metabolism.
Keywords: P-cadherin, Breast cancer, Hypoxia, Cancer stem cells* Correspondence: jparedes@ipatimup.pt
1IPATIMUP- Institute of Molecular Pathology and Immunology of the
University of Porto, Rua Dr Roberto Frias s/n, Porto 4200-465, Portugal
5FMUP- Faculty of Medicine of the University of Porto, Porto, Portugal
Full list of author information is available at the end of the article
© 2014 Sousa et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain
Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article,
unless otherwise stated.
Sousa et al. BMC Cancer 2014, 14:734 Page 2 of 13
http://www.biomedcentral.com/1471-2407/14/734Background
The tumor microenvironment is markedly defective on
oxygen and nutrients, which seems to have a huge influence
on the selection and survival of cancer stem cell
populations. In fact, it is widely accepted that developing
embryos, as well as regions of tissues with cells harboring
stem cell properties (stem cell niches), usually present low
oxygen tensions, suggesting hypoxia as a crucial event to
maintain the undifferentiated state of stem/progenitor
cells [1,2]. Additionally, it is already widely accepted that
undifferentiated cells, such as human embryonic stem
cells (hESC) and induced-pluripotent stem cells (iPSC),
present a glycolytic phenotype, decreased oxidative
phosphorylation and ROS (reactive oxygen species)
production, as well as altered lipid metabolism, when
compared to their normal differentiated counterparts [3].
Cancer cells with stem-like properties, also known as
cancer stem cells (CSC) or tumor-initiating cells (TICs),
are also thought to reside in hypoxic niches within the
tumor [2], exhibiting a metabolic program that allows
their survival in this aggressive microenvironment [3].
This metabolic reprogramming is now recognized as a
hallmark of cancer [4] and several players involved in
cell metabolism are currently being considered as targets
for cancer therapy [5].
HIF-1α, either induced by hypoxia or by alterations in
oncogenes and/or tumor suppressor genes, induces the
expression of gene products responsible for mediating
changes in energy metabolism, pH regulation, angiogenesis,
survival, invasion and motility [6]. In breast cancer, HIF-1α
expression is associated with high-grade tumors, loss of
estrogen receptor (ER), increased proliferation levels,
decreased disease-free and overall patient survival and also
with chemo- and radiotherapy resistance [7]. Moreover,
cancer cells usually require increased glucose consumption,
achieved by enhanced expression of glucose transporters
(such as GLUT1). The increased glycolysis leads to
intracellular acidosis that is controlled by upregulation of
other membrane transporters, such as carbonic anhydrase
IX (CAIX), monocarboxylate transporters (MCT1 and
MCT4) and CD147/EMMPRIN (an extracellular matrix
metalloproteinase inducer, required for proper location
and function of MCT1 and MCT4).
Interestingly, the adaptation of cancer cells to limited
oxygen availability, altered glucose metabolism and extra-
cellular acidosis, are linked to a poor patient prognosis in
breast cancer [8-10]. Chen et al. demonstrated that
hypoxia, glycolytic and acid-resistant phenotypes are a
powerful tumor cellular advantage and are associated
to an aggressive behavior of breast carcinomas [11].
Moreover, several studies have been reporting that basal-
like breast carcinomas (BLBC) show a stronger response to
hypoxia [8,10], as well as a higher glycolytic metabolism,
than tumors with luminal characteristics [12-16]. In fact,triple-negative and HER2-overexpressing breast carcinomas
present the higher tissue glucose metabolism, measured by
18 F-FDG PET scan, in comparison with the other
breast cancer molecular subtypes [17], reinforcing the
association between glycolytic metabolism and breast
cancer poor prognosis.
P-cadherin, a calcium dependent cell-cell adhesion
molecule encoded by the CDH3 gene, is a protein whose
expression is highly associated with undifferentiated cells
in normal adult epithelial tissues, as well as with poorly
differentiated carcinomas [18]. Its expression has been
already reported in hESCs and is presumed to be a
marker of stem or progenitor cells in epithelial tissues
[19,20]. During normal breast development, P-cadherin
has a crucial role in the ductal mammary branching,
being expressed by the monolayer of epithelial cap cells
at the terminal end buds (TEBs) [21]. Moreover, this
molecule is important for the undifferentiated state of
the normal mammary gland [19], with its expression
being restricted to the myoepithelium, although it has
been postulated that it may be also present in early
luminal progenitor cells [18,22,23]. In breast cancer,
P-cadherin is aberrantly expressed in high-grade in situ
[24] and invasive tumors [25], being a well-established
indicator of poor patient prognosis [18,22,26]. The
expression of P-cadherin is significantly associated with
basal-like molecular subtype [25], which is mainly charac-
terized by a triple-negative phenotype [ER, progesterone
receptor (PgR) and HER2 negativity] and by the expression
of basal/myoepithelial markers [27].
Moreover, P-cadherin expression promotes oncogenic-
associated effects in breast cancer [18,22]. Using in vitro
and in vivo models, we demonstrated that it induces
tumorigenesis, as well as cancer cell invasion partially
through the secretion of matrix metalloproteinases (MMPs),
such as MMP1 and MMP2 [28]. We have also disclosed
that P-cadherin functional role is dependent on E-cadherin
cellular context, since it interferes with the endogen-
ous cadherin/catenin complex, inducing p120-catenin
cytoplasmic delocalization and the consequent associated
alterations in the actin cytoskeleton [29].
Recently, our group demonstrated that P-cadherin
expression is associated with breast cancer stem cell
markers, namely CD44, CD49f and ALDH1 [30]. We
revealed that highly tumorigenic P-cadherin-enriched
breast cancer cell populations harbor increased survival,
resistance to radiation and stem cell properties [30].
Additionally, since it is accepted that breast cancer stem
cells are pro-glycolytic [31] and more resistant to radio-
therapy regimens [32], we hypothesized that the expression
of P-cadherin could be associated to cell populations with
an adapted phenotype to hypoxia and altered metabolism.
Interestingly, by the analysis of an online available gene
expression profile (E-GEOD-9649) [9], we could observe
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compared to normoxic conditions, as well as in response
to lactic acidosis.
In this work, we demonstrate that there is a significant
association between aberrant P-cadherin expression and
hypoxic, glycolytic and acid-resistant breast cancer
cells, suggesting a role for this epithelial basal marker
in cancer cell metabolism.
Methods
Breast tumor samples
Formalin-fixed, paraffin-embedded tissues of 473 invasive
breast carcinomas in Tissue Microarrays (TMAs) were re-
trieved from the histopathology files of three Departments
of Pathology: University Hospital of the Federal University
of Santa Catarina (UFSC, Florianópolis, Brazil), Hospital
Divino Espírito Santo (Ponta Delgada, Portugal) and from a
private Laboratory of Pathology (Veronese Patologia e
Citologia Araçatuba, Brazil). The tumors have been
characterized for clinical and pathological features (data are
summarized in Table S1 in Additional file 1). Molecular
characterization of this series was previously studied and
described [27]. This study was approved by the UFSC Eth-
ics Committee for Human Research (CEPSH), by the Ethics
Committee for Health from the Hospital do Divino Espírito
Santo de Ponta Delgada E.P.E., as well as by the research
review boards from the Veronese Patologia e Citologia
Araçatuba Pathology Laboratory. Patients have signed a
written informed consent, which implies that the spare
biological material, which has not been used for diagnosis,
can be used for research. This is in accordance with the
national regulative law for the handling of biological
specimens from tumor banks, being the samples exclusively
available for research purposes in retrospective studies, as
well as under the international Helsinki declaration.
Cell culture
Human breast cancer cell lines were obtained as follows:
BT20 was acquired from American Type Culture Collection
(Manassas, VA, USA) and SUM149 was kindly provided by
Dr. Stephen Ethier (University of Michigan, USA). Cells
were routinely maintained at 37°C, 5% CO2, in the following
media (Invitrogen Ltd, UK): DMEM for BT20 and 50%
DMEM/50% Ham-F12 for SUM149. In BT20, the media
contained 10% heat-inactivated fetal bovine serum, FBS,
(Greiner bio-one, Belgium) and in SUM149 cell line, media
was supplemented with 5% FBS, 5 μg/ml of insulin and
1 μg/ml of hydrocortisone (Sigma-Aldrich, USA). All
media were supplemented with 100 IU/ml penicillin
and 100 mg/ml streptomycin (Invitrogen Ltd, UK).
Primary antibodies
The following primary anti-human antibodies were used
for western blot (WB), immunohistochemistry (IHC)and flow cytometry (FC) against: P-cadherin [clone 56,
BD Transduction Biosciences, USA; diluted 1:500 (WB)
and 1:50 (IHC)], and APC-conjugated P-cadherin, R&D,
USA; diluted 1:10 (FC)], HIF-1α [clone 54, BD Transduction
Biosciences, USA; diluted 1:500 (WB) and 1:50 (IHC)],
CAIX [ab15086, AbCam, Cambridge, UK; diluted 1:1000
(WB), 1:2000 (IHC) and 1:10 (FC)], Glut1 [ab15309,
AbCam, Cambridge, UK; diluted 1:400 (WB), 1:500 (IHC)
and 1:10 (FC)], MCT1 [AB3538P, Chemicon International,
USA; diluted 1:200 (IHC)], MCT4 [AB3316P, Chemicon
International, USA; diluted 1:100 (IHC)], CD147 [18-7344,
Zymed Laboratories Inc., USA; diluted 1:750 (IHC)],
GAPDH [0411, Santa Cruz Biotechnologies, USA; diluted
1:10000 (WB)] and β-actin [clone I-19, Santa Cruz
Biotechnologies, USA; diluted 1:1000 (WB)].
Immunohistochemistry
The immunohistochemical assays were performed with spe-
cific antibodies for P-cadherin, HIF-1α, GLUT1, CAIX,
MCT1, MCT4 and CD147. Details about experimental
procedures, primary antibodies, antigen retrieval detection
systems and scoring are described elsewhere [12,13,27].
Specifically, HIF-1α immunohistochemistry was per-
formed using CSA, Catalyzed Signal Amplification System
(DAKOCytomation, USA), according to manufacturer’s
instructions. Reactions were independently evaluated by
two pathologists (FS and RG). All the proteins showed
membrane staining, consistent with their cellular function,
except for HIF-1α, which presented a nuclear pattern of ex-
pression and was considered positive whenever any strong
and dark nuclear staining was observed. For the different
antibodies studied, some samples could not be evaluated for
the 473 cases of the series due to TMA’s cores missing or to
insufficient representation of the tumor in the TMA core.
siRNA transfection
Gene silencing was performed with validated siRNA,
specific for CDH3 (50nM, Hs_CDH3_6), HIF-1α (50nM,
Hs_HIF1A_5), GLUT1 (100nM Hs_SLC2A1_2) and
CAIX (50nM, Hs_CA9_2). All siRNAs were from Qiagen
(USA). Transfections were carried out using Lipofecta-
mine 2000 (Invitrogen, UK), according to manufacturer’s
recommended procedures. After incubation for 5 minutes,
the siRNA and Lipofectamine 2000 solutions were mixed,
incubated for additional 20 minutes and added to cell
culture medium. A scrambled siRNA sequence, with no
homology to any gene, was used as a negative control
(Qiagen, USA). Gene inhibition was evaluated after
48 hours of cell transfection for CDH3, HIF-1α and GLUT1
and after 72 hours for CAIX.
CoCl2 treatment
Breast cancer cells were plated in T25 flasks for qRT-PCR
and FACS, or in coverslips for immunofluorescence. After
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chloride hexahydrate, Sigma-Aldrich, USA) diluted in
ethanol for 4 hours.
RNA extraction and qRT-PCR
RNA extraction was performed using RNeasy Mini Kit
(Qiagen, USA) and cDNA was synthesized using the
Omniscript Reverse Transcription kit (Qiagen, USA),
following the manufacturer’s instructions. Quantitative-
Real-Time-PCR (qRT-PCR) reaction was performed with
TaqMan Gene Expression Assays (Applied Biosystems,
USA), using gene-specific IDT probes (Integrated
DNA Technologies, Inc., USA): CDH3 (Hs.PT.51.5028751),
GLUT1 (Hs.PT.47.19044492.g), CAIX (Hs.PT.47.14063.g),
and GAPDH (Hs.PT.39a.22214836). Analysis was performed
with the ABI PRISM 7700 Sequence Detection System
Instrument and software (Applied Biosystems, USA),
following the manufacturer's recommendations. The
internal standard human GAPDH was used to normalize
cDNA quantity. Data was analyzed by the comparative 2
(-ΔΔCT) method [33]. For all data comparisons, the
Student's t-Test was used (two tailed, unequal variance).
All reactions were done in triplicate and the results
presented as mean of the values from three or more
independent experiments.
Immunofluorescence and confocal microscopic analysis
Cells were cultured on glass coverslips and 24 hours
later they were treated either with 200uM of CoCl2 or
with the respective vehicle (Ethanol) during 4 hours.
After that, cells were fixed with 4% paraformaldehyde
(20 minutes), treated with NH4Cl (50 mM) for 10 minutes,
washed with PBS, and permeabilized with 0.1% Triton
X-100 in PBS for 5 minutes, at room temperature.
Unspecific reactions were blocked with 30 minutes incuba-
tion of cells with blocking solution (5% BSA in PBS-tween
0,5%). Cells were then stained with the primary antibodies,
followed by incubation in the dark of Alexa488 or
Alexa-594-conjugated secondary IgG (Dako Cytomation,
Carpinteria, CA) in a 1:500 dilution. Primary and secondary
antibodies were diluted in blocking solution. Each sample
was mounted with Vectashield (Vector Laboratories,
Inc, Burlingame, CA) containing DAPI and visualized
with Leica SP5 confocal microscope (Leica Microsystems
GmbH, Germany). Volume of cells of both conditions was
acquired by Z-stack measurements.
FACS analysis and sorting
For FACS analysis, cells were harvested with versene/
0.48 mM EDTA (Invitrogen, UK), washed with PBS
supplemented with 0.5% FBS and re-suspended in the stain
buffer (2 mM EDTA and 0.5% bovine albumin in PBS).
Single cell suspension was labeled with APC-conjugated
P-cadherin, GLUT1 and CAIX antibodies. Cells transfectedwith the control siRNA and with CDH3 siRNA were dou-
bled stained either with P-cadherin and GLUT1 or CAIX
antibodies. A live-dead stain (Invitrogen, UK) and the
primary and secondary antibodies were incubated at
4°C, in the dark, for 15 minutes. Secondary Alexafluor-
488-conjugated goat anti-rabbit IgG (Invitrogen, UK) was
used in a 1:100 dilution. The labeled cells were then
washed in the stain buffer and analyzed on a FACS
Canto-II (BD Biosciences, USA).
For the sorting experiments, the subpopulations of
SUM149 and BT20 breast cancer cells were selected
according to P-cadherin expression (highest and lowest
20% expressing cells). Cells were sorted using BD Influx
or FACS ARIA-II (BD Biosciences) and collected into 10%
Hanks buffered solution (Invitrogen, UK). The purity of
sorted populations was 80-95%. In addition, a further
sample was also collected of cells passed through the laser
under pressure, but not sorted, to act as a control for the
effect of the pressure on the cells.
Protein extraction and western blot analysis
Protein lysates were prepared from sorted cells, using
catenin lysis buffer [1% (v/v) Triton X-100 and 1% (v/v)
NP-40 (Sigma-Aldrich, USA) in deionized phosphate-
buffered saline (PBS)] supplemented with 1:7 proteases
inhibitors cocktail (Roche Diagnostics GmbH, Germany)
for 10 min, at 4°C. Cell lysates were mixed with a vortex
and centrifuged at 14000 rpm at 4°C, during 10 min.
Supernatants were collected and protein concentration
was determined using the Bradford assay (BioRad Protein
Assay kit, USA). Proteins were dissolved in sample buffer
[Laemmli with 5% (v/v) 2-b-mercaptoethanol and 5% (v/v)
bromophenol blue] and boiled for 5 min at 95°C or
at 65° (for GLUT1 staining). Samples were separated
by SDS–PAGE and proteins were transferred into
nitrocellulose membranes [Amersham Hybond enhanced
chemiluminescence (ECL)]. For immunostaining, mem-
branes were blocked with 5% (w/v) non-fat dry milk in PBS
containing 0.5% (v/v) Tween20 and incubated during 1 hour
with anti-P-cadherin and anti-GAPDH, two hours
with anti- CAIX and anti- GLUT1 and overnight with
anti-HIF-1α. After washes with PBS-Tween20, membranes
were incubated with HRP-conjugated anti-mouse, goat or
rabbit secondary antibodies (Santa Cruz Biotechnologies,
USA) diluted 1:2000 for one hour. Proteins were then
detected using ECL reagent (Amersham, USA) as a
substrate. Quantity One software (BioRad, USA) was
used for quantification of the differences in protein
expression comparing with GAPDH expression.
Mammosphere forming efficiency (MFE) assay
After the 72 h of the siRNA transfection, cells were
enzymatically harvested and manually disaggregated
with a 25-gauge needle to form a single-cell suspension
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in nonadherent culture conditions, in flasks coated
with 1.2% poly(2-hydroxyethylmethacrylate)/95%ethanol
(Sigma-Aldrich, USA) and allowed to grow for 5 days, in
DMEM/F12 containing B27 supplement, and 500 ng/ml
hydrochortisone, 40 ng/ml insulin, 20 ng/ml EGF in a
humidified incubator at 37°C and 5% (v/v) CO2.
Mammosphere forming efficiency was calculated as the
number of mammospheres (≥50 μm) formed divided by
the cell number plated, being expressed as a percentage.
Statistical analysis
For immunohistochemistry results on breast cancer
samples, statistical analysis was performed by SPSS
statistics 17.0 software (SPSS Inc., USA). χ2 test and
contingency tables were used to determine associations
between groups and the results were considered
statistically significant when the p-value was lower
than 0.05. Concerning the functional in vitro assays, all
were performed independently and in triplicate. Data were
analyzed using the unpaired Student t test and considered
statistically significant when the P value was less than
0.05. Statistical analyses were performed using Office
Excel 2010 (Microsoft Corporation, Reading, UK). All
statistical tests were two-sided.
Results
P-cadherin overexpression is significantly associated with
the expression of hypoxic, glycolytic and acidosis markers
in primary invasive breast carcinomas
In a large series of invasive breast carcinomas, previously
classified for molecular subtypes [27], immunohistochemis-
try staining was performed for P-cadherin, HIF-1α, GLUT1,
CAIX, MCT1, MCT4, and CD147 (Figure 1). Membrane
P-cadherin expression was found in 145/468 (31%) of the
cases. Nuclear HIF-1α was considered positive in 104/315Figure 1 Immunoexpression of P-cadherin, HIF-1α, GLUT1, CAIX, MCT1,
staining for P-cadherin (A), HIF-1α (B), GLUT1 (C), CAIX (D), MCT1 (E), MCT4 (F
Images A, C, D, F and G are in 200x magnification; B and E are in 100X magn(33%) carcinomas. Concerning the membrane expression
of GLUT1, CAIX, MCT1, MCT4 and CD147, we observed
140/327 (42.8%), 66/316 (20.8%), 106/407 (26%), 69/419
(16.5%) and 24/217 (11%) positive cases, respectively.
Membrane GLUT1 and CAIX expression was frequently
detected in peri-necrotic tumor areas (Figure 1).
The association between the expression of each one of
these markers with the classical breast cancer prognostic
factors (Table S2 in Additional file 1) as well as with the
molecular subtypes and biomarkers ER, PgR, HER2 and
Ki67 (Table S3 in Additional file 1) was evaluated.
As previously reported, P-cadherin expression was
significantly associated with high-grade carcinomas
(p < 0.0001), HER2-overexpressing and basal-like molecular
subtypes (p < 0.0001), ER and PgR negativity (p < 0.0001),
high expression of HER2 (p < 0.0001), as well as with high
Ki67 (p = 0.0141). Accordingly, HIF-1α expression was also
associated with grade III (p < 0.0001) and high proliferative
(p = 0.0197) tumors. Concerning the expression of GLUT1,
CAIX, MCT1 and CD147, all have been significantly
associated with high-grade (p < 0.001), basal-like (p < 0.001),
ER and PgR negative (p < 0.05) tumors; absence of lymph
node metastasis was more frequently observed in MCT1
expressing tumors (p = 0.0223) and CAIX expression
was associated with an increased tumor size (p = 0.0005).
Additionally, the expression of GLUT1, MCT1 and CD147
was associated with high proliferation indexes measured
by Ki67 expression (p = 0.0339, p = 0.0297, p = 0.0179,
respectively). There was still an expected significant
association between the expression of hypoxic, glycolytic
and acid-resistant phenotype markers (Table S4 in
Additional file 1).
Interestingly, P-cadherin overexpression was also
significantly associated with the expression of HIF-1α
(p < 0.0001), GLUT1 (p < 0.0001), CAIX (p < 0.0001),
MCT1 (p = 0.0337) and CD147 (p < 0.0001) (Table S5MCT4 and CD147 in breast cancer samples. Immunohistochemical
) and CD147 (G) expression in primary invasive breast carcinomas.
ification. N: necrosis.
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found with MCT4 expression (p = 0.553). With this
data, we could demonstrate that breast carcinomas with
positive expression to HIF-1α, GLUT1, CAIX, MCT1 and
CD147 are significant associated to tumors showing a high
percentage of cancer cells stained for the basal epithelial
marker P-cadherin (Figure 2).
HIF-1α stabilization by CoCl2 increases membrane
P-cadherin expression in breast cancer cells
Due to the direct association found between P-cadherin
and HIF-1α expression in invasive breast carcinomas, as
well as to the described association between both
markers and the maintenance of stem-like properties,
we decided to evaluate if HIF-1α stabilization could be
affecting the expression of P-cadherin in breast cancer
cells. Furthermore, by the use of a bioinformatics prediction
tool [34,35], we were able to recognize a putative binding
site for HIF-1 transcription factor, positioned within a CpG
island of CDH3/P-cadherin promoter [36]. Thus, we treated
SUM149 breast cancer cells with CoCl2 in order to increase
the expression of HIF-1α (Figure 3A). Although there were
no alterations in CDH3mRNA levels (p = 0.562, Figure 3B),
we could observe, by FACS analysis, a statistically signifi-
cant increase of membrane P-cadherin expression upon
HIF-1α stabilization (p = 0.0246; Figure 3C). We confirmed
this result by confocal microscopy (Figure 3D), where
we noticed that CoCl2 treatment resulted in nuclear
accumulation of HIF-1α, as well as in an increased
expression of P-cadherin at the cell membrane, when
compared with cells treated only with the vehicle
(ethanol). Although not statistically significant (p = 0.0716),
we also observed a decrease in the cellular height after
CoCl2 treatment (Figure 3E), indicating a re-organization of
the cytoskeleton after HIF-1α stabilization, which can be
associated with the induction of P-cadherin expression.Figure 2 Aberrant P-cadherin expression in HIF-1α, GLUT1, CAIX, MCT
overexpression was significantly associated with the expression of HIF-1α, G
expression. *p < 0.05; **p < 0.0001.P-cadherin expression interferes with GLUT1 and CAIX
mRNA levels in breast cancer cells
The direct associations found in primary invasive breast
carcinomas established, for the first time, a connection
between P-cadherin expression and metabolic alterations
of tumor cells. Therefore, in order to find out if these
associations were reflecting a crosstalk between P-cadherin
expression and the metabolic shift experienced by breast
cancer cells, we decided to silence CDH3 transcripts by
siRNA-mediated knockdown in basal-like P-cadherin over-
expressing breast cancer cell models (BT20 and SUM149).
By real-time PCR, we could observe that CDH3 silencing
led to a statistically significant downregulation of GLUT1
and CAIX mRNA in BT20 breast cancer cells (p < 0.05)
(Figure 4A). Although not statistically significant, we could
also find a tendency to a decrease in GLUT1 and CAIX
mRNA levels in SUM149 breast cancer cells (Figure 4D).
No significant alterations were found in the mRNA expres-
sion of HIF-1α, MCT1 and CD147 upon CDH3 silencing in
both cell lines (Figure 4A and D). Interestingly, when
GLUT1 (Figure 4B and E) and CAIX (Figure 4C and F)
were silenced, there were no significant alterations in
CDH3 mRNA levels.
P-cadherin is co-expressed with GLUT1 and CAIX in
basal-like breast cancer cell lines
The above results led us to go further on the relationship
between P-cadherin and GLUT1 and CAIX, since we
observed that the expression of these both molecules
was being somewhat responsive to P-cadherin in
breast cancer cells. Thus, we decided to study if there was
an enrichment of P-cadherin expression in GLUT1 and/or
CAIX positive populations. Interestingly, we observed
that cells presenting the highest expression of P-cadherin
(20% high P-cad) were the ones also presenting the
highest expression of GLUT1 and CAIX, while the ones1, MCT4 and CD147 expressing breast carcinomas. P-cadherin
LUT1, CAIX, MCT1 and CD147. No association was found with MCT4
Figure 3 HIF-1α stabilization induces the expression of P-cadherin in the membrane of SUM149 breast cancer cells. HIF-1α stabilization
and accumulation by CoCl2 treatment was confirmed by western blot (A). qRT-PCR showed no significant alterations (p = 0.562) in CDH3 mRNA
levels upon CoCl2 treatment (B). Using FACS analysis, a statistically significant increase (p = 0.0246) was observed in the expression of membrane
P-cadherin in CoCl2 treated cells, when compared with the control cells treated with the vehicle (EtOH) (C). Immunofluorescence of CoCl2 treated
cells showed nuclear HIF-1α expression (red) and an increase of membrane P-cadherin expression (green), compared with vehicle treated cells
(D). Z-stack measurements revealed a decrease in the height of CoCl2-treated cells comparing with the control cells (E). *p < 0.05.
Sousa et al. BMC Cancer 2014, 14:734 Page 7 of 13
http://www.biomedcentral.com/1471-2407/14/734showing the lowest expression of P-cadherin (20% low
P-cad) demonstrated the lowest levels of GLUT1 and
CAIX (Figure 5A). This result was confirmed when we
sorted and separated the 20% high and low P-cadherin cell
populations and analyzed the expression of GLUT1 and
CAIX by western blot (Figure 5B). Furthermore, when
we selected the population of cells by their GLUT1
expression, the 20% high/low GLUT1 cells also presented
the highest and lowest levels of P-cadherin expres-
sion, respectively (Figure 5C). Still, the cells selected
by CAIX expression also presented the same tendency
concerning P-cadherin expression (Figure 5D). Similar
results were obtained in BT20 breast cancer cells
(Figure S1 in Additional file 2).
The inhibition of CDH3, HIF-1α, GLUT1 and CAIX affects
MFE in basal-like breast cancer cells
Our previous results show that HIF-1α stabilization was
accompanied by an increase of membrane P-cadherin
expression, which was co-expressed with GLUT1 and
CAIX in breast cancer cells. Since it has been already
described that HIF-1α, GLUT1 and CAIX are required
for CSC survival and tumor aggressiveness, and that wehave recently shown that P-cadherin is also involved in
the maintenance of stem-like properties of basal-like
breast CSCs, we decided to evaluate the effect of the
inhibition of all these molecules, alone or in combination,
on the mammosphere forming efficiency (MFE%) of the
SUM149 breast cancer cell model (Figure 6). As expected,
silencing the expression of CDH3, as well as of HIF-1α,
GLUT1 and CAIX, showed a significant decrease of the
ability to form mammospheres when compared with
the cells transfected with the control siRNA (p = 0.0153,
p = 0.0156, p = 0.000284 and p = 0.000902, respectively).
Moreover, when we simultaneously silenced CDH3 and
HIF-1α, we also observed a decrease of MFE of the target
cells (p = 0.0367), although not cumulative. If, in addition
to CDH3 and HIF-1α, we silence the downstream targets
GLUT1 and CAIX (siRNA CDH3 +HIF-1α +GLUT1 +
CAIX), there is still a non-cumulative decrease effect in
MFE (%) (p = 0.0152).
Discussion
Much attention has been paid to the tissue microenviron-
ment, highlighting the importance of hypoxia as a mediator
of cell survival, pluripotency, stemness and proliferation of
Figure 4 P-cadherin expression affects GLUT1 and CAIX mRNA levels in breast cancer cells. mRNA expression measured by qRT-PCR of
CDH3, HIF-1α, GLUT1, CAIX, MCT1 and CD147 when inducing siRNA-mediated knockdown of CDH3 , GLUT1 and CAIX in BT20 and
SUM149 breast cancer cell lines. Upon CDH3 silencing, there was a significant decrease of the mRNA expression of GLUT1 and CAIX in BT20
(A) and a tendency, although not statistically significant, to a decrease in SUM149 cells (D). No differences were observed in the mRNA expression of
HIF-1α, MCT1 and CD147 in both cell lines. On the other hand, there were no alterations in CDH3 mRNA expression in BT20 (B and C) and in SUM149
(E and F) breast cancer cell lines, when GLUT1 (B and E) and CAIX (C and F) were silenced. *p < 0.05; **p < 0.0001.
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http://www.biomedcentral.com/1471-2407/14/734normal stem cells [2,3] Alterations in metabolism have also
been proven to be important for the maintenance of stem
cell properties [3]. hESC and iPSC tends be more glycolytic
and less oxidative comparing to their somatic counterparts
[37-39]. Interestingly, the behavior of some tumor cells
resembles in many aspects the behavior of hESC, as well as
adult stem cells [3].
P-cadherin has been recently described as a mediator of
stem-like properties in basal-like breast cancer cell lines.
The main goal of this work was to understand if there was
an association between P-cadherin overexpression and
the phenotype of adaptation of breast cancer cells to
microenvironment stresses, such as hypoxia, lactic acidosis
and glycolytic metabolism, also characteristics of the
undifferentiated state of stem, progenitor and breast CSC.
Interestingly, we showed that P-cadherin is associated to
the hypoxic phenotype and metabolic reprogramming of
breast cancer cells.
We demonstrated an association between the expression
of P-cadherin and HIF-1α in breast carcinomas. Similarly
to P-cadherin, HIF-1α expression is associated to worse
prognosis in breast cancer, short patient’s survival, highproliferation and poor tumor differentiation [7,40].
Interestingly, we found that HIF-1α stabilization promotes
membrane P-cadherin expression in breast cancer cells,
although no alterations were detected in CDH3 mRNA
levels after CoCl2 treatment. With these results, we
can hypothesize that increased P-cadherin membrane
expression observed after HIF-1α accumulation occurs
at a post-transcriptional level, and not as a direct
effect. Thus, based on our findings and on previous
data reported by others, the crosstalk between these
molecules might be explained by several hypotheses.
Since hypoxia, through HIF-1α [41], is able to induce
ER degradation and that ER is a transcription CDH3
repressor [26,42], it is possible that hypoxia can be
inducing HIF-1α, promoting ER degradation and
allowing CDH3 transcription. Other possible explanation
is related to the link between hypoxia and BRCA1,
another CDH3 transcriptional repressor [43]. It is known
that hypoxia induces BRCA1 downregulation [44] and
that BRCA1-mutated breast carcinomas, which are
enriched in HIF-1α expression [45], present aberrant
expression of P-cadherin [46].
Figure 5 P-cadherin is co-expressed with GLUT1 and CAIX in basal-like breast cancer cell lines. By flow cytometry analysis, we observed
that the 20% of cells with the highest and lowest P-cadherin expression presented highest and lowest, respectively, expression of GLUT1 and
CAIX (A). When cells were sorted by P-cadherin expression, lysed and analyzed in SDS-PAGE, the same result was observed concerning the high and
low expression of GLUT1 and CAIX (B). On the other hand, 20% of cells with the highest and lowest levels of GLUT1 and CAIX (C and D, respectively)
expression also presented highest and lowest P-cadherin expression.
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http://www.biomedcentral.com/1471-2407/14/734Concomitantly with the increase of membrane P-cadherin
expression, we still observed a decrease in the cellular
height after CoCl2 stabilization, indicating a putative
re-organization of the cytoskeleton and cell morphology,
with the acquisition of a phenotype associated to breast can-
cer cell aggressiveness [47]. This observation is consistent
with our previous data, showing that P-cadherin expression
is able to induce invasion, migration and motility in breast
cancer cells [28] and that its modulation also inter-
feres with GTPase-mediated signal transduction and actin
cytoskeleton organization [29].
Our results also showed an association between
P-cadherin and GLUT1, CAIX, MCT1 and CD147. These
molecules are important response mediators of cancer cell
survival in stressful microenvironments and are upregulated
in poor prognosis BLBC [12,13], where P-cadherin is
aberrantly expressed. Upregulation of membrane trans-
porters, such as CAIX and MCTs, is responsible for the
extracellular acidification, assisting in vitro cancer cell
invasion and in vivo metastization through the acidic
degradation of the ECM [48]. CD147/EMMPRIN is
known to induce MMP production [49], such as MMP2
[50], to promote tumor growth, inhibit cell apoptosis and
enhance cell migration under hypoxic conditions [51].
Interestingly, the highly significant association found
between P-cadherin and CD147 is in accordance with the
above-described reports and also with our previous data,
showing that P-cadherin induces an invasive behavior inbreast cancer cells through the activation of MMP1 and
MMP2 [28].
Using basal-like breast cancer cell lines, we found that
P-cadherin silencing is able to induce the downregulation
of GLUT1 and CAIX mRNA, whereas GLUT1 and CAIX
knockdown showed little or no effect in CDH3 mRNA
expression. Thus, although the expression variations found
were not so prominent as expected for direct molecular
targets, we believe that P-cadherin is putatively involved
in a signaling pathway that interferes with the metabolic
reprograming of cancer cells. Moreover, we also demon-
strated that the cell subpopulation expressing more/less
P-cadherin at the cell surface was the same presenting
higher/lower levels of GLUT1 and CAIX and vice-versa.
These results suggests that P-cadherin overexpressing
breast cancer cells are most likely to exhibit increased
glycolysis and to survive to metabolic-driven pH alterations,
justifying the enhanced aggressive behavior and metastatic
properties.
In breast cancer, hypoxia and HIF-1α have a pivot role
in promoting tumor growth and metastasis through the
maintenance, expansion as well as increased activity of
breast CSCs [52-54]. Oliveira-Costa et al. showed that
HIF-1α was differently expressed in CD44+/CD24-/low
breast cancer cells [55]. Moreover, CAIX also plays a role
in the regulation of stemness and expansion of breast CSCs
in hypoxic niches [56]. Recently, our group demonstrated
that P-cadherin expression is able to mediate stem cell
Figure 6 MFE (%) decreases upon siRNA-mediated silencing of CDH3, HIF-1α, GLUT1 and CAIX in SUM149 cells. siRNA-mediated silencing
of CDH3, HIF-1α, GLUT1 and CAIX was confirmed by western blot analysis (A). A statistically significant decrease in MFE (%) was observed when
we silenced CDH3, HIF-1α, GLUT1 and CAIX. The simultaneous silencing of CDH3 and HIF-1α also revealed a significant decrease of MFE (%) of the
target cells, although not cumulative. Still, the silencing of the expression of all transcripts tested led to a non-cumulative inhibition of the MFE
compared to the control cells (B). *p < 0.05.
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http://www.biomedcentral.com/1471-2407/14/734properties in basal-like breast cancer cells [30]. Still,
we showed that BLBC, which are enriched in P-cadherin
expression, present a high percentage of cells with CSC
phenotype [57]. Accordingly, we demonstrated that the
inhibition of CDH3, HIF-1α, GLUT1 and CAIX in
basal-like breast cancer cells significantly reduces their
MFE, an important measure of breast cancer stem cell
activity. We still show that the silencing of CDH3 and
HIF-1α, or even the simultaneous inhibition of CDH3,
HIF-1α, GLUT1 and CAIX, have a non-cumulative effect
in the inhibition in MFE comparing to the single silencing
of any of these molecules. This result is in accordance with
our observation that the cell subpopulation expressingincreased levels of P-cadherin also presents higher levels of
GLUT1 and CAIX, demonstrating that we are targeting the
same breast cancer stem cell population.
Taking together, we believe that the hypoxic environment
in breast tumors might be selecting a pool of cancer cells
with stem-like properties, showing increased P-cadherin
expression as well as a distinct metabolic state. These
characteristics will be accounted for therapeutic resistance,
since breast CSCs are resistant to radiotherapy and are
thought to be responsible for breast cancer metastasis
[32,58]. Interestingly, previous data from our group also
demonstrated that P-cadherin inhibition sensitizes breast
cancer cells to radiation-induced cell death [30].
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In conclusion, we demonstrated that aberrant P-cadherin
expression is associated with the hypoxic/glycolytic and
acid-resistant phenotype in invasive breast carcinomas,
represented by a panel of markers including HIF-1α,
GLUT1, CAIX, MCT1 and CD147. We also showed that
membrane P-cadherin expression can be increased by
HIF-1α stabilization, as well as can modulate GLUT1 and
CAIX expression. Moreover, we still demonstrated that
P-cadherin is differentially expressed in basal-like breast
cancer cells that also present higher levels of GLUT1 and
CAIX. Thus, we believe that HIF-1α might be stabilizing
membrane P-cadherin expression in breast CSC or even
selecting P-cadherin-high expressing breast CSCs in the
hypoxic stem cell niche. In its turn, P-cadherin expression
is probably shifting the metabolic program of these cells,
which might be responsible for tumor aggressiveness, as
well as for their ability to survive, compared to the
low P-cadherin expressing cells. In this case, P-cadherin is
mediating the survival of aggressive cells thought to be
resistant to standard cancer therapies, being responsible for
tumor relapses and metastasis in breast cancer patients.Additional files
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